Regenxbio Inc Share Price Today: Live Updates & Key Insights

Regenxbio Inc share price today is $8.15, up -3.11%. The stock opened at $8.4 against the previous close of $8.36, with an intraday high of $8.43 and low of $8.07.

Regenxbio Inc Share Price Chart

Regenxbio Inc

us-stock
To Invest in {{usstockname}}
us-stock

Regenxbio Inc Share Price Performance

$8.15 -0.0311(-3.11%) RGNX at 23 Mar 2026 03:01 PM Biotechnology
Lowest Today 8.07
Highest Today 8.43
Today’s Open 8.4
Prev. Close 8.36
52 Week High 16.19
52 Week Low 5.04
Day’s Range: Low 8.07 High 8.43
52-Week Range: Low 5.04 High 16.19
1 day return -
1 Week return -7.62
1 month return +2.46
3 month return -45.9
6 month return -10.32
1 year return -6.98
3 year return -58.84
5 year return -79.3
10 year return -

Regenxbio Inc Institutional Holdings

JPMorgan Chase & Co 15.64

BlackRock Inc 12.34

Redmile Group, LLC 9.09

Vanguard Group Inc 6.54

State Street Corp 3.85

The Goldman Sachs Group Inc 3.59

Morgan Stanley - Brokerage Accounts 3.30

Vanguard Total Stock Mkt Idx Inv 2.77

JPMorgan Small Cap Growth A 2.71

AQR Capital Management LLC 2.64

Assenagon Asset Management SA 2.25

Geode Capital Management, LLC 2.22

iShares Russell 2000 ETF 2.21

Integral Health Asset Management, LLC 2.13

State Street® SPDR® S&P® Biotech ETF 1.91

22NW, LP 1.79

Dimensional Fund Advisors, Inc. 1.75

Invesco S&P 500 ETF 1.42

Nuveen, LLC 1.28

Vanguard Institutional Extnd Mkt Idx Tr 1.00

Pale Fire Capital SE 0.97

Nuveen Quant Small Cap Equity R6 0.91

Fidelity Small Cap Index 0.89

JPMorgan Small Cap Blend A 0.86

Qube Research & Technologies 0.86

Bank of America Corp 0.80

iShares Russell 2000 Value ETF 0.80

Northern Trust Corp 0.78

Acadian Asset Management LLC 0.77

Charles Schwab Investment Management Inc 0.76

Vanguard Strategic Small-Cap Equity Inv 0.73

iShares Biotechnology ETF 0.67

BlackRock Advantage Small Cap Core Instl 0.67

Invenomic Institutional 0.66

JPM Thematics Genetic Thrps C2 dist USD 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

Fidelity Enhanced Small Cap ETF 0.54

Stt Strt®SPDR®S&PKenshoNwEcosComposETF 0.52

Fidelity Extended Market Index 0.48

Multi-Manager Small Cap Eq Strat Inst 0.47

Regenxbio Inc Market Status

Strong Buy: 6

Buy: 5

Hold: 1

Sell: 0

Strong Sell: 0

Regenxbio Inc Fundamentals

Market Cap 418.07 M

PB Ratio 4.2001

PE Ratio 0.0

Enterprise Value 274.92 M

Total Assets 453.03 M

Volume 2687263

Regenxbio Inc Company Financials

Annual Revenue FY23:99374000 99.4M, FY22:112724000 112.7M, FY21:470347000 470.3M, FY20:154567000 154.6M, FY19:35233000 35.2M

Annual Profit FY23:60616000 60.6M, FY22:58179000 58.2M, FY21:418514000 418.5M, FY20:118853000 118.9M, FY19:26992000 27.0M

Annual Net worth FY23:-260540000 -260.5M, FY22:-280321000 -280.3M, FY21:127840000 127.8M, FY20:-111250000 -111.3M, FY19:-94733000 -94.7M

Quarterly Revenue Q3/2025:29733000 29.7M, Q2/2025:21359000 21.4M, Q1/2025:89012000 89.0M, Q3/2024:24197000 24.2M, Q2/2024:22295000 22.3M

Quarterly Profit Q3/2025:-32093000 -32.1M, Q2/2025:12245000 12.2M, Q1/2025:85576000 85.6M, Q3/2024:11810000 11.8M, Q2/2024:7665000 7.7M

Quarterly Net worth Q3/2025:-61941000 -61.9M, Q2/2025:-70871000 -70.9M, Q1/2025:6083000 6.1M, Q3/2024:-59597000 -59.6M, Q2/2024:-52989000 -53.0M

About Regenxbio Inc & investment objective

Company Information REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Organisation Biotechnology

Employees 371

Industry Biotechnology

CEO Mr. Curran M. Simpson M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Regenxbio Inc FAQs

What is the share price of Regenxbio Inc today?

The current share price of Regenxbio Inc is $8.15.

Can I buy Regenxbio Inc shares in India?

Yes, Indian investors can buy Regenxbio Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Regenxbio Inc shares in India?

You can easily invest in Regenxbio Inc shares from India by:

Can I buy fractional shares of Regenxbio Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Regenxbio Inc?

Regenxbio Inc has a market cap of $418.07 M.

In which sector does Regenxbio Inc belong?

Regenxbio Inc operates in the Biotechnology sector.

What documents are required to invest in Regenxbio Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Regenxbio Inc?

The PE ratio of Regenxbio Inc is N/A and the PB ratio is 4.20.